Neurizon Therapeutics Limited (ASX: NUZ) — Neurizon Executes Long-Term Supply Agreement with Elanco, Strengthening Commercialisation Readiness

17 June 2026

Price Sensitive Announcement $

Highlights:

• Neurizon has executed a long-term supply agreement with Elanco Animal Health, securing an initial five-year term for access to GMP monepantel — the active pharmaceutical ingredient in Neurizon’s lead asset, NUZ-001
• The agreement provides scalable Good Manufacturing Practice supply, representing an important commercialisation milestone and materially strengthening Neurizon’s long-term manufacturing and supply chain readiness
• The supply agreement builds on the parties’ previously executed global licence agreement (announced 2 July 2025), reflecting continued confidence in NUZ-001’s clinical development as a potential ALS and broader neurodegenerative disease therapy
• Neurizon will exclusively acquire monepantel from Elanco, with a right to manufacture or source functionally equivalent API from a third party in specifically identified circumstances
• Initial orders are intended to support commercialisation and the creation of a strategic inventory holding
• The agreement is supported by a separate Quality Agreement allocating responsibilities for GMP manufacturing, quality control, batch release and change management
• Commercialisation of NUZ-001 remains subject to successful clinical development and regulatory approval, with the asset currently progressing through the Phase 2/3 HEALEY ALS platform trial

Overview:

Neurizon Therapeutics has taken a significant step toward commercialisation readiness for its lead asset NUZ-001, executing a long-term supply agreement with Elanco Animal Health that secures scalable GMP access to monepantel — the active pharmaceutical ingredient underpinning the Company’s ALS and neurodegenerative disease program.

The five-year agreement builds directly on the global licence agreement Neurizon and Elanco established in mid-2025, extending the relationship into critical supply chain territory as NUZ-001 advances through the Phase 2/3 HEALEY ALS platform trial. By locking in long-term, high-quality monepantel supply manufactured to human pharmaceutical specifications, Neurizon strengthens both its Chemistry, Manufacturing and Controls (CMC) infrastructure and its broader regulatory readiness — supporting manufacturing consistency across both clinical and any future commercial development activities.

The agreement also reflects a disciplined approach to capital management, providing Neurizon with supply certainty without requiring significant upfront manufacturing investment. Initial orders under the agreement are intended to support commercialisation activities and build a strategic inventory holding, while Neurizon retains the right to request deferral of supply pending regulatory approval — providing flexibility as the clinical program progresses.

With supply security now in place alongside its existing licensing arrangement with Elanco, Neurizon is positioning NUZ-001 as an increasingly attractive proposition for potential pharmaceutical partners and strategic investors, while continuing to build out its broader neurodegenerative disease development platform.

Company Notes:

Neurizon Interim Executive Chairman Sergio Duchini said the agreement represents a critical milestone in the continued advancement of the NUZ-001 program and furthers the Company’s relationship with Elanco. He noted the agreement strengthens Neurizon’s long-term manufacturing and supply framework, supporting potential future commercialisation and operational scalability following completion of the Phase 2/3 program. Duchini described the arrangement as reflecting a disciplined, risk-managed approach to capital management, and said that combined with the existing licence agreement, the supply arrangement further enhances the strategic and commercial foundation underpinning NUZ-001 — strengthening Neurizon’s positioning as a clinically advanced and commercially focused neurodegenerative disease company.

About Neurizon Therapeutics Limited (ASX: NUZ & NUZOA | OTCQB: NUZTF):

Neurizon Therapeutics is a late-stage clinical biotech company dedicated to advancing innovative treatments for neurodegenerative diseases. The Company’s lead asset, NUZ-001, is progressing through the Phase 2/3 HEALEY ALS platform trial as a potential therapy for ALS and broader neurodegenerative conditions. Neurizon has an established global licence and supply relationship with Elanco Animal Health, providing long-term access to GMP monepantel — the active pharmaceutical ingredient in NUZ-001 — as the Company builds toward future commercialisation, subject to successful clinical development and regulatory approval.

Disclaimer: This article is based on a company ASX announcement and is intended for general informational purposes only. It does not constitute financial advice. The Stock Connect may receive fees for content services. Readers should conduct their own research and consult a licensed financial advisor before making any investment decisions.